Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
European Journal of Cancer2017Vol. 79, pp. 119–128
Citations Over TimeTop 10% of 2017 papers
Loïc Lebellec, Bruno Chauffert, Jean‐Yves Blay, Axel Le Cesne, Christine Chevreau, Emmanuelle Bompas, François Bertucci, Didier Cupissol, Michel Fabbro, Esma Saâda-Bouzid, Florence Duffaud, L. Feuvret, Alice Bonneville-Levard, Jacques‐Olivier Bay, Élodie Vauléon, Armelle Vinceneux, G. Noël, Nicolas Penel, Olivier Mir
Related Papers
- → Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma(2009)154 cited
- The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells.(2019)
- → Sorafenib and sunitinib for elderly patients with renal cell carcinoma(2013)8 cited
- Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.(2014)
- → Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma(2019)3 cited